¼¼°èÀÇ °¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀå
Gas Exchange Pulmonary Function Testing
»óǰÄÚµå : 1774863
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 471 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è °¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀåÀº 2030³â±îÁö 3¾ï 1,940¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 2¾ï 4,480¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â °¡½º ±³È¯ Æó±â´É °Ë»ç ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 3¾ï 1,940¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÈÞ´ë¿ë ½Ã½ºÅÛÀº CAGR 5.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 870¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íÁ¤Çü ½Ã½ºÅÛ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 3.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6,670¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀåÀº 2024³â¿¡ 6,670¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 8.4%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 6,680¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.8%¿Í 3.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ °¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È£Èí±â °Ç°­ °ü¸®¿¡¼­ °¡½º ±³È¯ Æó ±â´É °Ë»ç°¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°¡½º ±³È¯ Æó±â´É °Ë»ç(PFT)´Â Æó ±â´ÉÀ» Æò°¡ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Æó¿Í Ç÷·ù »çÀÌ¿¡¼­ »ê¼Ò¿Í ÀÌ»êȭź¼Ò°¡ ¾ó¸¶³ª È¿À²ÀûÀ¸·Î À̵¿ÇÏ´ÂÁö¸¦ ÃøÁ¤ÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), õ½Ä, Æó¼¶À¯Áõ, °£Áú¼º ÆóÁúȯ°ú °°Àº È£Èí±â ÁúȯÀÇ Áø´Ü°ú °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. °¡Àå ÀϹÝÀûÀÎ °¡½º ±³È¯ °Ë»ç·Î´Â Æó ÀÏ»êȭź¼Ò È®»ê´É(DLCO)°ú µ¿¸ÆÇ÷ °¡½º(ABG) ºÐ¼®ÀÌ ÀÖÀ¸¸ç, ÆóÀÇ °Ç°­°ú »ê¼ÒÈ­ È¿À²¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â Àǻ簡 Áúº´ÀÇ ½É°¢¼ºÀ» ÆÇ´ÜÇϰí, Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϸç, Ä¡·á °èȹÀÇ È¿°ú¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

´ë±â¿À¿°, Èí¿¬, Á÷¾÷Àû À§Çè, Äڷγª19ÀÇ Àå±âÀûÀÎ ¿µÇâ µîÀ¸·Î ÀÎÇÑ È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Æó ±â´É °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù. º´¿ø, Áø·á¼Ò, Áø´Ü ½ÇÇè½Ç´Â Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃã Ä¡·á Àü·«À» °³¼±Çϱâ À§ÇØ Ã·´Ü °¡½º ±³È¯ °Ë»ç Àåºñ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÈÞ´ë¿ë PFT Àåºñ ¹× ºñħ½ÀÀû ¸ð´ÏÅ͸µ µµ±¸¿Í °°Àº ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ƯÈ÷ ¿Üµý Áö¿ªÀ̳ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ Æó ±â´É Æò°¡¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î È£Èí±â °Ç°­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥, °¡½º±³È¯Æó±â´É°Ë»ç´Â È£Èí±â Ä¡·á¿Í Áúº´ ¿¹¹æÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

Æó±â´É °Ë»ç ±â¼úÀÇ ÁÖ¿ä ¹ßÀüÀº?

Æó±â´É °Ë»ç ºÐ¾ß¿¡¼­´Â Á¤È®¼º, È¿À²¼º ¹× ȯÀÚ ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀÌ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â ±â¼ú Çõ½Å Áß Çϳª´Â º¸´Ù ³ôÀº Á¤È®µµ·Î ½Ç½Ã°£ Æó ±â´É µ¥ÀÌÅ͸¦ Á¦°øÇÏ´Â µðÁöÅÐ ÆóȰ·® ÃøÁ¤ ¹× ¸ÆÆÄ °Ë»ç ½Ã½ºÅÛÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Æó ±â´ÉÀÇ ÆÐÅÏÀ» ½Äº°Çϱâ À§ÇØ AI ±â¹Ý ºÐ¼®À» ÅëÇÕÇÏ¿© Áúº´À» Á¶±â¿¡ Áø´ÜÇÏ°í ¸ÂÃã Ä¡·á¹ýÀ» ÃßõÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¶ÇÇÑ, ¿þ¾î·¯ºí È£Èí ¸ð´ÏÅ͸µ ±â±âÀÇ µµÀÔÀ¸·Î ¸¸¼º È£Èí±â Áúȯ ȯÀÚÀÇ Æó ±â´ÉÀ» Áö¼ÓÀûÀ¸·Î ÃßÀûÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ºñħ½ÀÀûÀ̰í ÈÞ´ë °¡´ÉÇÑ °¡½º ±³È¯ °Ë»ç ¼Ö·ç¼ÇÀº Æó Áø´ÜÇп¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ ÀüÅëÀûÀÎ º´¿ø ȯ°æ ¹Û¿¡¼­ °Ë»ç¸¦ ¼öÇàÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀçÅà PFT Àåºñ´Â ¸¸¼º ÆóÁúȯ ȯÀÚµé »çÀÌ¿¡¼­ Àα⸦ ¾ò°í ÀÖÀ¸¸ç, Æí¸®ÇÔ°ú ÀÇ·á Àü¹®°¡¿ÍÀÇ ½Ç½Ã°£ µ¥ÀÌÅÍ °øÀ¯¸¦ Á¦°øÇÕ´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í Æó ±â´É °Ë»çÀÇ ÅëÇÕÀ¸·Î ¿ø°Ý ȯÀÚ °ü¸®°¡ ´õ¿í °­È­µÇ¾î Àǻ簡 Á÷Á¢ ¹æ¹®ÇÏÁö ¾Ê°íµµ Æó °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ µðÁöÅÐ ÀüȯÀ» °è¼Ó ¹Þ¾ÆµéÀ̰í ÀÖ´Â °¡¿îµ¥, Æó±â´É °Ë»ç ±â¼úÀÇ ¹ßÀüÀº Áúº´ÀÇ Á¶±â ¹ß°ß°ú ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

°¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

°¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº È£Èí±â ÁúȯÀÇ ºÎ´ã Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡, COPD, õ½Ä, Æó¼¶À¯Áõ, ȯ°æ ¿À¿° ¹°Áú, Èí¿¬, Á÷¾÷Àû À§ÇèÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î COPD, õ½Ä, Æó¼¶À¯ÁõÀÇ À¯º´·üÀÌ ±ÞÁõÇϰí ÀÖ¾î ±¤¹üÀ§ÇÑ Æó±â´É Æò°¡°¡ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÇÊ¿äÇÕ´Ï´Ù. ³ëÀÎÀº È£Èí±â Áúȯ¿¡ °É¸®±â ½±±â ¶§¹®¿¡ Á¤±âÀûÀÎ Æó±â´É °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç°ú AI ±â¹Ý Áø´ÜÀÇ µµÀÔÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ½º¸¶Æ® È£Èí±â ¸ð´ÏÅ͸µ µµ±¸¸¦ Ȱ¿ëÇÏ¿© Áúº´À» Á¶±â¿¡ ¹ß°ßÇϰí Ä¡·á¸¦ ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æó °Ç°­¿¡ ´ëÇÑ Àνİú °ËÁø ÇÁ·Î±×·¥À» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀ¸·Î Æó ±â´É °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼­ºñ½º¿Í ÈÞ´ë¿ë Áø´Ü ÀåºñÀÇ ÅëÇÕÀº ¿ø°Ý Æó ±â´É ¸ð´ÏÅ͸µ, ƯÈ÷ ³óÃÌ Áö¿ª°ú ¼Ò¿ÜµÈ Áö¿ª¿¡¼­ ¿ø°Ý Æó ±â´É ¸ð´ÏÅ͸µÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀüÀÌ È£Èí±â Áø´ÜÀÇ ÇüŸ¦ °è¼Ó º¯È­½Ã۰í Àֱ⠶§¹®¿¡ °¡½º ±³È¯ Æó±â´É °Ë»ç ½ÃÀåÀº ±â¼ú Çõ½Å, ÀÇ·á ¼ö¿ä Áõ°¡, Á¤È®ÇÑ ½Ç½Ã°£ Æó±â´É Æò°¡¿¡ ´ëÇÑ ¼ö¿ä¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

½Ã½ºÅÛ À¯Çü(ÈÞ´ë¿ë ½Ã½ºÅÛ, °íÁ¤Çü ½Ã½ºÅÛ), °Ë»ç ¹æ¹ý(°¡½º È®»ê ½ÃÇè, ½ÉÆó ¿îµ¿ ºÎÇÏ ½ÃÇè), ¿ëµµ(¸¸¼º Æó¼â¼º ÆóÁúȯ ¿ëµµ, õ½Ä ¿ëµµ, ¸¸¼º È£Èí °ï¶õ ¿ëµµ, Æó ¼¶À¯Áõ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ, Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gas Exchange Pulmonary Function Testing Market to Reach US$319.4 Million by 2030

The global market for Gas Exchange Pulmonary Function Testing estimated at US$244.8 Million in the year 2024, is expected to reach US$319.4 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Portable System, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$208.7 Million by the end of the analysis period. Growth in the Stationary System segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$66.7 Million While China is Forecast to Grow at 8.4% CAGR

The Gas Exchange Pulmonary Function Testing market in the U.S. is estimated at US$66.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$66.8 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Gas Exchange Pulmonary Function Testing Market - Key Trends & Drivers Summarized

Why Is Gas Exchange Pulmonary Function Testing Crucial in Respiratory Health Management?

Gas exchange pulmonary function testing (PFT) plays a vital role in assessing lung function, measuring how efficiently oxygen and carbon dioxide are transferred between the lungs and bloodstream. These tests are essential for diagnosing and managing respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and interstitial lung diseases. The most common gas exchange tests include the diffusing capacity of the lungs for carbon monoxide (DLCO) and arterial blood gas (ABG) analysis, which provide crucial insights into lung health and oxygenation efficiency. These tests help physicians determine disease severity, monitor disease progression, and evaluate the effectiveness of treatment plans.

The increasing prevalence of respiratory diseases, driven by factors such as air pollution, smoking, occupational hazards, and the long-term impact of COVID-19, has amplified the demand for pulmonary function testing. Hospitals, clinics, and diagnostic laboratories are investing in advanced gas exchange testing equipment to improve early disease detection and personalized treatment strategies. Furthermore, technological advancements such as portable PFT devices and non-invasive monitoring tools have expanded accessibility to lung function assessments, particularly in remote or underserved regions. As global respiratory health concerns continue to rise, gas exchange pulmonary function testing remains a cornerstone of respiratory care and disease prevention.

What Are the Key Developments in Pulmonary Function Testing Technology?

The field of pulmonary function testing has witnessed significant technological advancements, enhancing accuracy, efficiency, and patient comfort. One of the most impactful innovations is the development of digital spirometry and plethysmography systems, which provide real-time lung function data with greater precision. These systems integrate AI-driven analytics to identify patterns in lung function, aiding in early disease diagnosis and personalized treatment recommendations. Additionally, the adoption of wearable respiratory monitoring devices has enabled continuous tracking of lung function in patients with chronic respiratory conditions.

Non-invasive and portable gas exchange testing solutions are also transforming pulmonary diagnostics, allowing healthcare providers to conduct tests outside traditional hospital settings. Home-based PFT devices are gaining popularity among patients with chronic lung diseases, offering convenience and real-time data sharing with healthcare professionals. The integration of telemedicine with pulmonary function testing has further enhanced remote patient management, enabling physicians to monitor lung health without requiring in-person visits. As healthcare systems continue to embrace digital transformation, the evolution of pulmonary function testing technologies is expected to improve early disease detection and patient outcomes.

Which Factors Are Driving the Expansion of the Gas Exchange Pulmonary Function Testing Market?

The growth in the gas exchange pulmonary function testing market is driven by several factors, including the rising burden of respiratory diseases, advancements in diagnostic technologies, and increased healthcare expenditure. The global prevalence of COPD, asthma, and pulmonary fibrosis has surged due to environmental pollutants, smoking, and occupational hazards, necessitating widespread lung function assessments. The aging population is another significant factor, as elderly individuals are more susceptible to respiratory conditions, driving demand for routine pulmonary function testing.

The adoption of digital health solutions and AI-powered diagnostics is also accelerating market growth, with healthcare providers leveraging smart respiratory monitoring tools for early disease detection and treatment optimization. Additionally, government initiatives promoting lung health awareness and screening programs have expanded the accessibility of pulmonary function tests. The increasing integration of telehealth services and portable diagnostic devices has further facilitated remote lung function monitoring, particularly in rural and underserved regions. As technological advancements continue to reshape respiratory diagnostics, the gas exchange pulmonary function testing market is expected to witness sustained growth, driven by innovation, rising healthcare needs, and the demand for precise, real-time lung function assessments.

SCOPE OF STUDY:

The report analyzes the Gas Exchange Pulmonary Function Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

System Type (Portable System, Stationary System); Test Method (Gas Diffusion Tests, Cardiopulmonary Exercise Testing); Application (Chronic Obstructive Pulmonary Disease Application, Asthma Application, Chronic Shortness of Breath Application, Pulmonary Fibrosis Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Centers End-Use, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â